Next Article in Journal
A Metabolomics Approach to Pharmacotherapy Personalization
Previous Article in Journal
Gene-Metabolite Interaction in the One Carbon Metabolism Pathway: Predictors of Colorectal Cancer in Multi-Ethnic Families
Article Menu
Issue 3 (September) cover image

Export Article

Open AccessArticle
J. Pers. Med. 2018, 8(3), 27; https://doi.org/10.3390/jpm8030027

Design of a Controlled Trial of Cascade Screening for Hypercholesterolemia: The (CASH) Study

1
Department of Cardiovascular Diseases and the Gonda Vascular Center, Mayo Clinic, Rochester, MN 55902, USA
2
Department of Health Sciences Research (KRB), Mayo Clinic, Rochester, MN 55902, USA
*
Author to whom correspondence should be addressed.
Received: 22 May 2018 / Revised: 17 July 2018 / Accepted: 25 July 2018 / Published: 23 August 2018
Full-Text   |   PDF [1420 KB, uploaded 23 August 2018]   |  

Abstract

To inform guidelines for screening family members of patients with familial hypercholesterolemia (FH), we designed a clinical trial to compare the yield of cascade screening in FH patients with and without an identifiable pathogenic variant. Participants with hypercholesterolemia (Low-density lipoprotein cholesterol (LDL-C) > 155 mg/dL) underwent sequencing of LDLR, APOB, and PCSK9 and genotyping of six single nucleotide polymorphisms associated with LDL-C followed by calculation of a polygenic score for LDL-C. We identified 24 patients with definite FH (pathogenic variant in one of the three FH genes), 76 patients with probable FH (Dutch lipid clinic network (DLCN) score ≥ 6, no pathogenic variant), and 262 patients with possible FH (DLCN score 3–5, no pathogenic variant). We will enroll 50 patients with definite FH by recruiting an additional 26 from the FH Clinic at Mayo and 50 patients each with probable and possible FH, matching on age and sex. Family members of patients with definite FH will undergo testing for the relevant pathogenic variant using saliva kits and family members of those with probable/possible FH will have a lipid profile checked. We will assess the number of new cases detected (defined as presence of a pathogenic variant in the family member of definite FH patient or LDL-C > 155 mg/dL (>130 mg/dL in children) in family members of probable/possible FH patients, and the cost of detecting a new case. The proposed clinical trial will compare the yield and cost of cascade screening for FH patients with/without an identifiable pathogenic variant, and thereby inform guidelines for cascade screening for FH. View Full-Text
Keywords: clinical trial; design; familial hypercholesterolemia; cascade screening; genetics; genetic risk; genetic testing; personalized medicine clinical trial; design; familial hypercholesterolemia; cascade screening; genetics; genetic risk; genetic testing; personalized medicine
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Kullo, I.J.; Bailey, K.R. Design of a Controlled Trial of Cascade Screening for Hypercholesterolemia: The (CASH) Study. J. Pers. Med. 2018, 8, 27.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Pers. Med. EISSN 2075-4426 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top